Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > NR says R107 is 99.99 percent effective.

<< Previous

Bullboard Posts

Next >>

Comment by Bigginvestoron Mar 03, 2021 9:32pm

185 Views

Post# 32711921

RE:RE:NR says R107 is 99.99 percent effective.

Jer0n wrote: Be careful of the wording of the release, and don't get confused between a proven licensed vaccine (e.g. Phizer) and a potential anti-viral ...
"Dr. Salzman continued,“We are delighted to be working with Claritas to develop R-107, not only as a therapy for vaccine-resistant COVID-19 infection but also as a broad-spectrum antiviral drug for the treatment and possible prevention of future viral outbreaks, including viruses that cause influenza and the common cold.”

cheer

go to global News wire it tells u 99.9 percent . like really man smh.!!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing